Navigation Links
Pervasis Receives Orphan Drug Designation in Europe for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
Date:3/1/2011

s proprietary endothelial cell-based platform to prevent solid tumor growth, cancer recurrence and metastatic disease.

About Pervasis Pervasis Therapeutics, Inc. is a clinical stage company that is developing groundbreaking endothelial cell-based therapies designed to regulate the body's natural healing and repair processes in various critical therapeutic areas. The company has initially focused on developing therapies to improve the outcomes of common vascular interventions, such as arteriovenous access, angioplasties, stent placements, and peripheral and coronary bypass grafts – the failure of which result in serious complications and a significant increase in medical costs. The company's lead program, Vascugel®, has demonstrated proof of concept and safety in two Phase 2 clinical trials. Pervasis is also applying its endothelial cell-based platform technology to develop an oncology therapy focused on preventing solid tumor growth, cancer recurrence and metastatic disease, as well as products for inflammatory disease and orthopedic injury.

Pervasis is a privately held company with funding from Flagship Ventures, Polaris Venture Partners, Highland Capital Partners and the Richter Family Fund. For more information, please visit www.pervasistx.com.  

This news release contains certain forward-looking statements that involve risks and uncertainties. Such statements are only predictions and the company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the timing of clinical trials, the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in clinical trials and the risk that the company will not obtain approval to market its products.

(1)  Dixon et al. DAC Study Group. Effect of dipyridamole plus aspirin on he
'/>"/>

SOURCE Pervasis Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pervasis Receives FDA Fast Track Status for Vascugel® to Prevent Arteriovenous Access Failure in Patients Undergoing Hemodialysis
2. Pervasis to Present Interim Data from Phase 1/2 Clinical Study of Novel Cell Therapy Targeting Peripheral Artery Disease at International Conference on Cell Therapy for Cardiovascular Diseases
3. Pervasis Therapeutics to Develop Novel Cell-Based Approach to Target Tumor Environment, Prevent Cancer Recurrence
4. Pervasis Therapeutics Awarded Four Grants Under the Qualifying Therapeutic Discovery Project
5. Pervasis Therapeutics Receives FDA Clearance for Pivotal Phase 3 Trial of Vascugel(R)
6. Mylan Receives Approval for Generic Version of Neurontin® Capsules
7. Elektas Oncology-Specific MOSAIQ Receives Complete ONC-ATCB EMR Certification
8. ViewRay Receives FDA 510(k) Marketing Clearance for Treatment Planning and Delivery Software
9. Vapotherm® Receives FDA 510(k) Clearance for Flowrest® Homecare Device
10. Delcath Systems Receives Refusal to File Letter From FDA
11. Prima BioMed Receives Regulatory Scientific Advice on CVac Phase III Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Ohio , Jan. 15, 2014  A novel wearable injector ... easy and painless for patients to self-inject prescription drugs in ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to grow to $220B by 2018, according to analysts.   Many ...
(Date:1/14/2014)... AUSTIN, Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... report results for the fourth quarter of 2013 on Monday, ... scheduled for release after the close of trading. ... a conference call to discuss the operating highlights and financial ...
(Date:1/14/2014)... Calif. , Jan. 14, 2014 The Brandeis Medical Center, ... Angeles a premier and affordable laser tattoo removal experience ... Dr. Brandeis, focus is in providing high quality cosmetic services with ... patients. " Southern California has seen ...
Breaking Medicine Technology:Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... 2011 Omeros Corporation (Nasdaq: OMER ) today ... Regents of the University of California to a new series ... advance in the control of surgical and traumatic bleeding. ... represents a potential life-saving treatment for patients. With the withdrawal ...
... 5, 2011 CutisPharma, Inc. announced the introduction ... Mary,s Mouthwash compounding kits. These products complete the ... line already includes FIRST® - Mouthwash BLM, and ... FIRST® - Duke,s Mouthwash are comparable to those ...
Cached Medicine Technology:Omeros Licenses Novel Antifibrinolytic Agents 2Omeros Licenses Novel Antifibrinolytic Agents 3Omeros Licenses Novel Antifibrinolytic Agents 4CutisPharma Launches New Prescription Mouthwash Kits Expanding Product Line 2
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... MAYWOOD, Il. (April 17, 2014) Doctors who ... disease called lymphangioleiomyomatosis (LAM) can face an agonizing ... progression of the disease and help relieve shortness ... lung transplants, and sirolimus can cause potentially fatal ... said pulmonologist Dr. Daniel Dilling, medical director of ...
(Date:4/17/2014)... Boston University School of Medicine (BUSM) have discovered ... in an experimental model. The findings, reported in ... Abuse , may lead to more effective treatments ... one of the leading causes of illness and ... economic impact by limiting the productivity of workers ...
(Date:4/17/2014)... NEW YORK (17 April 2014) Population Council scientists and ... is safe, stable, and can prevent the transmission of ... and rectum in animals: HIV, herpes simplex virus 2 ... provides the first data that the gel is effective ... of efficacy in the vagina against all three viruses ...
Breaking Medicine News(10 mins):Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Animal study provides first evidence that gel can prevent multiple virus transmission in vagina/rectum 2
... Dr Mukesh Haikerwal, today congratulated the Government on a ... // with the AMA, and which delivers for patients. ... that the draconian conditions and red tape associated with ... ,'The Government has agreed that the expertise in prescribing ...
... especially the mentally-ill patients and their caregivers. The speech revived ... which would permit the use of obligatory powers to enable ... present ‘treatability test’. ,The infamous ‘Bournewood gap’ is ... of the new bill, which will seek to improve the ...
... banned the use of hookah, or hubble-bubble, in the Pakistani ... were spoiling the younger// generation. ,A way of ... South Asia and the Middle East, the hookah, known as ... and motels in Pakistan, The Daily Times said. ...
... more delays in getting the lab results! - Says ... from University of Georgia has developed a diagnostic test using ... influenza, HIV, RSV etc., in just 60 seconds or even ... technique – which is detailed in the November issue of ...
... that about one in 10 U.S. adults suffer chronic pain that ... Americans have increased to a record average of just short of ... from the Centers for Disease Control and Prevention. ,The ... 80 years and nearly 75 for males. The gap in life ...
... know that they shouldn't smoke or be around smokers ... at a young age. In addition, a new research ... could develop serious liver injuries due to the effects ... research performed at Washington University School of Medicine in ...
Cached Medicine News:Health News:Government Strikes Right Balance with PBS Reform 2Health News:Nanotechnology Used For Detecting Viruses 2Health News:Nanotechnology Used For Detecting Viruses 3Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 2Health News:Non-Steroidal Anti-Inflammatory Drugs Can Cause Liver Damages 3
... PLUS pachometers are acknowledged to be the ... pachometers available. These benefits are due to ... and smallest tip footprint available coupled with ... for every displayed reading. Thus corneal thickness ...
... versatile and uncomplicated use of the Leica ... obtained make it the instrument of choice ... cryostat applications. The open top stainless steel ... accessible and offers ample space for convenient ...
... the new style of Bright cryostat. ... OTF/AS cryostat, the new OTF5000 incorporates ... ever-reliable and powerful 5040 microtome. A ... package deals makes the range of ...
... The Leica TP1020 product family are ... a perfect combination of approved technology with ... processing and maximum safety for tissues at ... engineering design based on proven precision mechanics ...
Medicine Products: